301 related articles for article (PubMed ID: 24243140)
1. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Curtis NJ; Noble F; Bailey IS; Kelly JJ; Byrne JP; Underwood TJ
J Surg Oncol; 2014 Mar; 109(3):202-7. PubMed ID: 24243140
[TBL] [Abstract][Full Text] [Related]
2. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
[TBL] [Abstract][Full Text] [Related]
3. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma.
Mitchell KG; Ikoma N; Nelson DB; Maru DM; Erasmus JJ; Weston BR; Vaporciyan AA; Antonoff MB; Mehran RJ; Rice DC; Roth JA; Swisher SG; Sepesi B; Walsh GL; Correa AM; Das P; Blum MA; Badgwell BD; Hofstetter WL
Ann Thorac Surg; 2019 Sep; 108(3):845-851. PubMed ID: 31102632
[TBL] [Abstract][Full Text] [Related]
4. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
5. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
6. Differences in prognosis of Siewert II and III oesophagogastric junction cancers are determined by the baseline tumour staging but not its anatomical location.
Kulig P; Sierzega M; Pach R; Kolodziejczyk P; Kulig J;
Eur J Surg Oncol; 2016 Aug; 42(8):1215-21. PubMed ID: 27241921
[TBL] [Abstract][Full Text] [Related]
7. Proximal margin length with transhiatal gastrectomy for Siewert type II and III adenocarcinomas of the oesophagogastric junction.
Mine S; Sano T; Hiki N; Yamada K; Kosuga T; Nunobe S; Yamaguchi T
Br J Surg; 2013 Jul; 100(8):1050-4. PubMed ID: 23754647
[TBL] [Abstract][Full Text] [Related]
8. [Survival comparison of Siewert II adenocarcinoma of esophagogastric junction between transthoracic and transabdominal approaches:a joint data analysis of thoracic and gastrointestinal surgery].
Yang S; Yuan Y; Hu H; Li R; Liu K; Zhang W; Yang K; Yang Y; Bai D; Chen X; Zhou Z; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):132-142. PubMed ID: 30799535
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
10. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
11. Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction.
Reeh M; Mina S; Bockhorn M; Kutup A; Nentwich MF; Marx A; Sauter G; Rösch T; Izbicki JR; Bogoevski D
Br J Surg; 2012 Oct; 99(10):1406-14. PubMed ID: 22961520
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.
Alderson D; Cunningham D; Nankivell M; Blazeby JM; Griffin SM; Crellin A; Grabsch HI; Langer R; Pritchard S; Okines A; Krysztopik R; Coxon F; Thompson J; Falk S; Robb C; Stenning S; Langley RE
Lancet Oncol; 2017 Sep; 18(9):1249-1260. PubMed ID: 28784312
[TBL] [Abstract][Full Text] [Related]
13. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Waddell T; Chau I; Cunningham D; Gonzalez D; Okines AF; Okines C; Wotherspoon A; Saffery C; Middleton G; Wadsley J; Ferry D; Mansoor W; Crosby T; Coxon F; Smith D; Waters J; Iveson T; Falk S; Slater S; Peckitt C; Barbachano Y
Lancet Oncol; 2013 May; 14(6):481-9. PubMed ID: 23594787
[TBL] [Abstract][Full Text] [Related]
14. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P
Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of the superiority of different TNM staging systems in Siewert III adenocarcinoma of esophagogastric junction].
Lu Y; Xi H; Xie T; Qiu Z; Wang X; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):143-148. PubMed ID: 30799536
[TBL] [Abstract][Full Text] [Related]
16. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
Noble F; Lloyd MA; Turkington R; Griffiths E; O'Donovan M; O'Neill JR; Mercer S; Parsons SL; Fitzgerald RC; Underwood TJ;
Br J Surg; 2017 Dec; 104(13):1816-1828. PubMed ID: 28944954
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Cunningham D; Okines AF; Ashley S
N Engl J Med; 2010 Mar; 362(9):858-9. PubMed ID: 20200397
[No Abstract] [Full Text] [Related]
18. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
19. Contemporary outcomes for resected type 1-3 gastroesophageal junction adenocarcinoma: a single-center experience.
Stiles ZE; Hagerty BL; Brady M; Mukherjee S; Hochwald SN; Kukar M
J Gastrointest Surg; 2024 May; 28(5):634-639. PubMed ID: 38704200
[TBL] [Abstract][Full Text] [Related]
20. Adenocarcinomas of the esophagogastric junction: experiences at a single institution in China.
Zhang H; Wang W; Cheng Y; Song Y; Zhu K; Dang C
World J Surg Oncol; 2013 Jul; 11():155. PubMed ID: 23849250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
